e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
The role of hormones and cytokines in lung injury
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The effects of angiotensin II and related peptides on intracellular Ca2+ release in human lung fibroblasts
S. Maitland, A. Sampson, J. Warner, D. Hall (Southampton, Stevenage, United Kingdom)
Source:
Annual Congress 2013 –The role of hormones and cytokines in lung injury
Session:
The role of hormones and cytokines in lung injury
Session type:
Thematic Poster Session
Number:
3926
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Maitland, A. Sampson, J. Warner, D. Hall (Southampton, Stevenage, United Kingdom). The effects of angiotensin II and related peptides on intracellular Ca2+ release in human lung fibroblasts. Eur Respir J 2013; 42: Suppl. 57, 3926
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
The increased contractility of idiopathic pulmonary fibrosis lung fibroblasts is dependent on angiotensin signalling
Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease
Year: 2010
Effect of in vivo blockade of the KCa3.1 ion channel on type II alveolar epithelial cell turnover in pulmonary fibrosis
Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Role of endothelin in lung fibrosis
Source: Eur Respir Rev 2008; 17: 145-150
Year: 2008
Treprostinil effectively inhibits PDGF and TGF-ß1 induced extracellular matrix composition by IPF fibroblasts
Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Year: 2015
In vivo blockade of KCa3.1 ion channel alleviates ER stress in type II alveolar epithelial cells and macrophages in pulmonary fibrosis
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019
Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014
Angiotensin II antagonism fails to ameliorate bleomycin-induced pulmonary fibrosis in mice
Source: Eur Respir J 2005; 25: 708-714
Year: 2005
KCa3.1 channel inhibition prevents fibrotic responses in a human lung explant model
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
Collagen V activation and matrix extracellular remodeling mediated pulmonary fibrosis in experimental models of bleomycin and 3-5-di-tert-4-hidroxitoluene
Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation
Year: 2013
Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Blocking endothelin: breaking new ground
Source: Eur Respir Rev 2008; 17: 24-29
Year: 2007
Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension?
Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018
Year: 2018
Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2012; 21: 152-160
Year: 2012
Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: Role of transmembrane SCF and PAR-2/PKCalpha/Raf-1/p44/42 signaling pathway
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
The role of extracellular vesicles in phenotypic alteration of lung cells in pulmonary fibrosis
Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Year: 2013
Inhibition of collagen cross-links by novel LOXL2 selective inhibitors in an in-vitro model of fibroblastic foci of IPF
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD)
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept